Processa Pharmaceuticals, Inc.

NASDAQ: PCSA · Healthcare · Biotechnology

PublicHQ Hanover, MDCIK 0001533743Reports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

38D

FH 26DQ 57GM 34SS 42

v0.1 · 65/100 weight · provisional

↑ filing timeliness, balance-sheet leverage · ↓ 3-yr revenue growth, Piotroski F

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$13.6M

Employees

Market cap

$4.9M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02022

Net income-$13.6M-$13.6M2025

Operating income-$14.0M-$14.0M2025

Total assets$7.8M$7.8M2025

Liabilities$2.2M$2.2M2025

Equity$5.6M$5.6M2025

Revenue trend

FY2013 – FY2022 · USD

$192.1k

FY13

$520.2k

FY13

$200.2k

FY14

$113.4k

FY15

$5.0k

FY16

FY21

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Processa Pharmaceuticals, Inc. booked $0 in FY2022 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Mosaic ImmunoEngineering Inc.——Healthy Extracts Inc.67B PharmaCyte Biotech, Inc.61C Tempest Therapeutics, Inc.26D

Key facts

CEOGeorge K. Ng

SectorHealthcare

IndustryBiotechnology

HeadquartersHanover, MD

ExchangeNASDAQ: PCSA

Employees10

IPO date2014-03-07

Latest filings

DEF 14A2026-06-18 10-Q2026-05-07 8-K2026-04-30 10-K2026-03-18 8-K2026-02-19 8-K2026-01-07 8-K2025-12-15 10-Q2025-11-06

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.